-
2 days ago | 
ddw-online.com | Megan Thomas
DDW’s Megan Thomas attended Nebius’ inaugural AI Discovery Awards in Amsterdam, where top prizes of $100,000 in GPU credits were awarded to four companies pioneering AI breakthroughs in cancer prediction, protein targeting, transcriptomic mapping, and precision diagnostics.
-
3 days ago | 
ddw-online.com | Megan Thomas
Both online and in the DDW quarterly magazine, DDW editors interview industry researchers to shine a spotlight on their work in a feature called Meet the Researcher. A question often included is: If you could make everyone read one book, article or academic paper, what would it be and why? Here, DDW’s Megan Thomas compiles a reading list featuring the books suggested by these researchers.
-
3 days ago | 
ddw-online.com | Megan Thomas
France’s National Research Agency (ANR) and Defense Innovation Agency (AID) will finance the BUNYANTIVIR project to introduce a novel therapeutic approach for Bunyaviricetes’ class of human pathogenic viruses found in tropical and subtropical regions.
-
3 days ago | 
ddw-online.com | Megan Thomas
The Longitude Prize on ALS is a new £7.5 million ($10.28 million) global challenge prize to incentivise and reward cutting edge AI-based approaches to transform drug discovery for the treatment of amyotrophic lateral scleosis (ALS), the most common form of motor neuron disease (MND). Open for entries from 25 June 2025 until 3 December 2025, it will initially award 20 teams £100,000 each in early 2026, with one team going on to win £1 million at the end of the five-year prize.
-
3 days ago | 
ddw-online.com | Megan Thomas
In the In Conversation With series, a part of the free DDW podcast, DDW speaks with members of the drug discovery industry about their work and how it helps turn science into business. In this episode, Megan Thomas is in conversation with Professor Jonathan Kagan, a Harvard immunology professor and director of Basic Research at Boston Children’s Hospital.
-
4 days ago | 
ddw-online.com | Megan Thomas
Qureight’s digitally-twinned synthetic control arm has been used in a breakthrough clinical trial application in place of a human placebo group, marking a world-first in lung disease research. The study, presented at the American Thoracic Society, demonstrates significant clinical efficacy for Avalyn’s inhaled pirfenidone (AP01), a promising treatment for idiopathic pulmonary fibrosis (IPF), a rare and high-mortality lung disease.
-
6 days ago | 
ddw-online.com | Megan Thomas
The latest episode of the DDW Highlights podcast is now available to listen to below. DDW’s Megan Thomas narrates five key stories of the week to keep DDW subscribers up-to-date on the latest industry updates. In the same week DDW shared expert insights from the 2025 ASCO annual meeting, there have been several significant developments in oncology drug discovery, including new therapy options for some difficult to treat cancers.
-
1 week ago | 
ddw-online.com | Megan Thomas
This year’s American Society of Clinical Oncology (ASCO) Annual Meeting took place at the McCormick Place Convention Center in Chicago from 30 May to 3 June 2025. DDW’s Megan Thomas collected commentary from industry experts in attendance. CCR8 therapies gain clinical significance Stephan Schann is Chief Scientific Officer at Domain Therapeutics, a French biotech delivering G protein-coupled receptors (GPCR)-targeting therapies to immuno-oncology and inflammation patients.
-
1 week ago | 
ddw-online.com | Megan Thomas
DDW’s Megan Thomas speaks with ICON’s Chief Information Officer, Tom O’Leary, about leveraging artificial intelligence (AI) to enhance efficiency, decision-making, and patient outcomes across the drug development lifecycle, from early feasibility to post-marketing. MT: Could you provide an overview of your findings when it comes to drug development and AI?
-
1 week ago | 
ddw-online.com | Megan Thomas
The latest episode of the DDW Highlights podcast is now available to listen to below. DDW’s Megan Thomas narrates five key stories of the week to keep DDW subscribers up-to-date on the latest industry updates. This week’s round-up highlights the vital role of genetics in drug discovery, including new data for an Alzheimer’s gene therapy, the discovery of a genetic target for rejuvenation therapies, and a 13-year follow up on haemophilia gene therapy patients.
